Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Abstract: In this work, we present a contribution on the applicability of the recursive least squares method used for the parametric identification of a corona discharge phenomenon at small distances.

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Abstract: This letter presents a novel method for environmental exploration that takes safety into account in unknown areas by using recursive Gaussian process regression (RGPR). Safety in unknown ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

The world's highest-profile and most watched awards show, which has aired on ABC since 1976, will be moving to a streaming-only platform starting as part of a deal that also includes red carpet ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

YouTube has launched its first-ever personalized end-of-year summary called YouTube Recap. The feature shows users their top videos, genres, and music, and assigns a personality type based on viewing ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Recursion Pharmaceuticals merged with Exscientia, another AI-driven drug discovery company, positioning itself as a potential biotech innovator The company has partnerships with major pharmaceutical ...